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ABSTRACT
Motivation: Cancer is a complex disease that in-
volves rapidly evolving cells, often forming multi-
ple distinct clones. In order to effectively understand
progression of a patient-specific tumor, one needs
to comprehensively sample tumor DNA at multiple
time points, ideally obtained through inexpensive
and minimally invasive techniques. Current sequenc-
ing technologies make the ‘liquid biopsy’ possible,
which involves sampling a patient’s blood or urine
and sequencing the circulating cell free DNA (cfDNA).
A certain percentage of this DNA originates from the
tumor, known as circulating tumor DNA (ctDNA). The
ratio of ctDNA may be extremely low in the sam-
ple, and the ctDNA may originate from multiple tu-
mors or clones. These factors present unique chal-
lenges for applying existing tools and workflows to
the analysis of ctDNA, especially in the detection
of structural variations which rely on sufficient read
coverage to be detectable. Results: Here we intro-
duce SViCT , a structural variation (SV) detection tool
designed to handle the challenges associated with
cfDNA analysis. SViCT can detect breakpoints and
sequences of various structural variations including
deletions, insertions, inversions, duplications and
translocations. SViCT extracts discordant read pairs,
one-end anchors and soft-clipped/split reads, as-
sembles them into contigs, and re-maps contig inter-
vals to a reference genome using an efficient k-mer
indexing approach. The intervals are then joined us-
ing a combination of graph and greedy algorithms to
identify specific structural variant signatures. We as-
sessed the performance of SViCT and compared it to
state-of-the-art tools using simulated cfDNA datasets
with properties matching those of real cfDNA sam-
ples. The positive predictive value and sensitivity of
our tool was superior to all the tested tools and rea-
sonable performance was maintained down to the
lowest dilution of 0.01% tumor DNA in simulated
datasets. Additionally, SViCT was able to detect all
known SVs in two real cfDNA reference datasets (at
0.6–5% ctDNA) and predict a novel structural vari-
ant in a prostate cancer cohort. Availability: SViCT is
available at https://github.com/vpc-ccg/svict. Con-
tact: faraz.hach@ubc.ca
INTRODUCTION
A current challenge in precision oncology is the ability to
track the progress of tumor in the patients; e.g. response
to treatment. The classical approach for this would be to
conduct tissue biopsies at different time points. This is an
expensive and time consuming process, and since this in an
invasive procedure, it may be difficult for the patient. Fur-
thermore, if the tumor has undergone metastasis, biopsies
become even more difficult or impossible. Amore attractive
alternative would be to sequence circulating cell free DNA
(cfDNA) from the patient’s blood or urine, which does not
suffer from these drawbacks.
The existence of cfDNA has been known for decades,
with its discovery in 1948 (1). Such DNA arises in the blood
primarily through cell apoptosis, necrosis, and active release
(2). A certain portion of these cells, and consequentlyDNA,
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may derive from a tumor and is known as circulating tumor
DNA (ctDNA) (3). In fact, it has been shown that cfDNA
levels are elevated as much as 200 times in cancer patients
compared to healthy controls (2). The proportion of ctDNA
varies greatly between patients (0.003% to 95%) (4,5), and
tends to be lower in early stage tumors over advanced dis-
ease ormetastasis (6). Note that ctDNAmay originate from
any tumor site (can be primary or metastatic) and any tu-
mor subpopulation/clone.
Single locus assays using quantitative PCR (qPCR) or
droplet digital PCR (ddPCR) have been successfully used
for detectingmutations in leukemia, pancreatic and colorec-
tal cancer (7–9). More recently, NGS approaches have been
used to detect variants in lung and prostate cancer (10,11),
which allow covering more loci within a single run at the
cost of reduced sensitivity (12,13). Since our approach relies
on NGS data, sensitivity is restricted due to the limits of the
sequencing technology in samples with very low amounts of
ctDNA. In these cases, in order to have sufficient read cov-
erage, sequencing is done at very high depth (typically 20
000×, can be 90 000× or more). Generally, whole exome or
targeted sequencing is used to accomplish this.
The circulating fragments are often very short, with the
modal length (167 bp) being related to length of DNA that
wraps around a nucleosome (∼147 bp) (6).Many fragments
are even shorter, between 50 bp and 166 bp, which can
be more effectively detected using single-stranded DNA li-
brary preparation (14). Since typical short sequencing reads
are 75 bp to 150 bp, paired end sequencing may result in the
majority of read pairs having both read ends overlapping
each other and many reads being shorter than the target
length. Although these short fragments are most common,
much longer fragments (>1000 bp) can also be observed (6).
The variability inDNA sources and fragment lengths, along
with very high sequencing depth, results in noisy data that
may confound general purpose, genomic analysis tools.
In this study, our focus is on genomic structural varia-
tion (SV) detection through the use of cfDNA. Genomic
structural variants are alterations to the genome that in-
volve more than a single (typically ≥5) base pair. Major
SV types include deletions, insertions, duplications (tandem
or interspersed) and inversions. If any of these occur over
a very large genomic distance, or involve sequences from
different chromosomes, they are known as translocations.
When a SV causes exons from different genes to become ad-
jacent they form a gene fusion. Fusions and SVs observed in
exonic regionsmay lead to aberrant protein products or pre-
vent translation altogether and have been associated with
disease conditions and especially with cancer. A well known
example are fusions of TMPRSS2 and the ETS gene family
in prostate cancer (15).
Since the introduction of the first methods for genomic
structural variant detection such as VariationHunter (16),
the field of structural variant detection has matured, with
many tools using a variety of approaches. What is com-
mon between all tools is the use of discordant reads and/or
split reads as an indicator of a structural variant. A discor-
dant mapping of a paired end read is one that either inverts
one or both of the read ends, or has a significantly differ-
ent distance between the read ends than what is expected.
A one-end anchor is a mapping of a paired end read for
which a mapping of only one of the read ends is present;
the other end remains unmapped. A split read mapping of
a read end is one that partitions a read end into two and
aligns them to two distant loci. If the prefix or suffix of a
read end is too short to be effectively mapped, that read be-
comes soft-clipped. Existing tools make use of these struc-
tural variant indicators in a variety of ways. For example,
Breakdancer (17) and VariationHunter (16) use discordant
mappings only, while others such as Socrates (18) usemostly
split or soft-clipped reads. A combination of these strategies
are employed by other tools such as Lumpy2 (19), GRIDSS
(20), Pindel (21),Delly2 (22). The effectiveness of these tools
on cfDNAhas not been investigated and, to our knowledge,
no SV callers exist which are tailored for cfDNA. Specifi-
cally, it is unknown whether these callers can handle (i) very
high read depth, (ii) extremely low dilutions, (iii) variable
read lengths, (iv) high heterogeneity, and (v) high system-
atic noise.
These challenges motivated us to develop
SViCT (Structural Variation detection in Circulating
Tumor DNA), the first SV caller tailored for cfDNA.
SViCT starts with sequencing data in standard BAM
format and through a combination of assembly, k-mer
mapping and graph-based algorithms, predicts all major
classes of structural variants. The predictions include
base-pair resolution of breakpoints, SV type annotation,
genomic context annotation (including fusions) and
coordinates/sequence of the source DNA. The perfor-
mance of the tool was assessed using a simulated cfDNA
dataset, including 10%, 1%, 0.5% and 0.01% dilutions.
SViCTmaintained good sensitivity even at the lowest dilu-
tion and outperformed existing SV callers. The sensitivity
was further assessed on real, reference datasets, where
SViCTwas the only tool of those tested to find all the
known variants. Finally, SViCTwas applied to a cohort
of eight metastatic, castration resistant prostate cancer
(CRPC) patient samples, discovering a number of high
confidence structural variants.
MATERIALS AND METHODS
SViCTpredicts genomic, tumor specific structural variants
through the use of cfDNA in five subsequent stages: (i)
extraction and clustering of (discordant) one end anchors
(OEA) and soft-clipped/split reads, (ii) local assembly of
each cluster into contigs, (iii) contig k-mer indexing and
mapping to the reference, (iv) chaining of mapped inter-
vals and computation of optimal chained mappings and (v)
structural variant and fusion identification. A summary of
SViCT stages, using a simple example, is provided in Fig-
ure 1 and details for each stage are given in the following
subsections.
Read extraction and clustering
SViCTaccepts aligned reads (SAM/BAM files) as input,
and extracts all discordant, one-end anchors (OEA), soft-
clipped, and split reads from the input file. The approach
is not protocol specific, i.e. any standard biotinylated probe
capture protocol can be used for read sequencing. In prin-
ciple, standard whole genome sequencing reads can also be
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Figure 1. Overview of the SViCT algorithm, using an example with four
soft-clipped reads and twoOEAs. (A) Soft-clipped reads are extracted from
BAM files and clustered based on their soft-clip location. OEAs with one
read end mapped nearby are added to the cluster. (B) The unmapped or
partially unmapped read ends are assembled into contigs. (C) Contigs are
indexed and all consecutive reference k-mers are mapped to each contig.
(D) All intervals associated with a contig are used to create a graph repre-
senting valid multi-interval mappings and an optimal set of suchmappings
is derived from the graph. (E) The intervals are used to determine the SV
signature.
used. In cfDNA, the fragment lengths are generally shorter
than the typical read length, i.e. the two read endsmay over-
lap considerably. As a consequence, if a breakpoint falls in a
read, it will likely be present in both read ends. In that case,
one or both read end(s) will be either unmappable, or, more
likely, mapped with soft clipping or split mapped. And so,
we use the soft-clip/split position to guide the clustering.
For reads with a split-mapping, (i.e. reads that can be par-
titioned into a prefix and a complementary suffix, mapping
to two distant loci) both loci are considered for clustering. If
a read end has multiple soft-clip mapping positions, a copy
of the read end is created for each possibility.
SViCT sorts the extracted soft-clipped/split read ends
based on the mapping position at the clip/split point. All
read ends that have the ‘same’ soft-clip/split mapping po-
sition (within 3 bp by default) are included in a breakpoint
specific cluster through the use of a sliding window. Note
that each read end, for each of its soft-clip mapping posi-
tions, could be a part of up to three clusters (for each win-
dow of length 3 bp covering it). SViCT initially treats these
multiple clusters independently, even though they could be
merged in subsequent stages. Each cluster of read end map-
pings is then assembled to obtain a longer contig.
Although soft-clipped and split mapping reads make
up the vast majority of read mappings, reads originating
from an SV region may produce discordant read map-
pings or one-end anchors. In order to maximize sen-
sitivity, SViCTalso includes these reads in its analysis.
Since such read mappings do not contain a breakpoint,
SViCT considers all possible clusters they could be a part
of. Each unmapped read end of an OEA is thus included
in every cluster formed by soft-clip/split mappings whose
implied breakpoint is within an expected fragment length
distance to its mapped read end.
Among discordantly mapped reads, SViCT considers
those reads whose ends have ‘the same’ orientation (one
read end is incorrect) and reads whose ends have ‘differ-
ent’ orientations but both read ends are incorrect. If the two
ends are indeed with the same orientations, the incorrectly
oriented read end is included in each relevant cluster as de-
scribed for one-end anchors. If the read ends have different
orientations, we treat each read end separately and include
its mapping in each relevant cluster, again as described for
one-end anchors.
Local assembly and probabilistic filtering
For the assembly stage, we use a modified version of the
overlap-layout-consensus (OLC) assembly algorithm some
of us have developed for the Pamir (23) pipeline. This al-
gorithm aims to maximize the total amount of overlaps be-
tween reads, which it models as an instance of themaximum
weighted path problem in a directed acyclic graph (DAG).
For that SViCTbuilds a directed graph, where each read is
represented as a vertex such that any pair of vertices where
the associated reads have a prefix-suffix overlap have an
edge between them. The weight of the edge is the length
of the maximum possible overlap between the two reads.
(In principle, this graph may have cycles; see Kavak et al.
(23) for a description of the procedure to remove such cy-
cles.) Provided that the resulting graph is a DAG, the opti-
mal maximum weighted path, which represents the optimal
assembly of reads, can be computed through a dynamic pro-
gramming formulation (again see Kavak et al. (23) for a de-
scription of this formulation).
The above algorithm requires that the reads are all dis-
tinct - which is typically not the case for cfDNAdue to read-
end overlaps. Not only could there be reads that are identi-
cal (in such cases all but one of the reads are eliminated), it
is also possible to have one read be a substring of another.
SViCT identifies such substring pairs (by a variant of Karp–
Rabin fingerprinting technique (24)) and initially discards
the shorter string in favor of the longer one. Once the ‘op-
timal’ assembly is complete with the remaining reads, the
initially removed shorter reads are incorporated into their
respective contigs.
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Since the clustering procedure may identify many po-
tentially overlapping contigs (e.g. clusters sharing read
mappings are likely to produce overlapping contigs)
SViCTapplies a probabilistic filter to reduce the number of
contigs. Given a contig of length n including m reads with
an average read length l, let the distances between the start-
ing points of consecutive reads in the contig be 1, 2, . . . ,
m and let  = max{1. . .m}. Under the null model, for
any two consecutive reads, the probability of having no gap
(a distance of 1) between them is p = m/(n − l), and the
probability of having a distance ≥ between them is (1 −
p). The intuition here is that all positions on the contig
must be covered by a read, and all reads must overlap. Con-
sequently, there are a fixed number of positions where the
prefix of a read can overlap with the suffix of the previous
read, which is the length of the contig divided by the number
of reads. The reciprocal of this is the probability of the read
starting at any one of these positions, assuming the reads
are uniformly and independently distributed. Since the pre-
fix of the first read and the suffix of the last read have no
overlap, with combined length relative to l, this calculation
is corrected by subtracting l from n. For m − 1 consecutive
read pairs, the probability of having no pair with a distance
≥κ is (1 − (1 − p))(m − 1) and thus the probability the max-
imum distance between consecutive reads ≥κ is: P(m, ) =
1 − (1 − (1 − p))(m − 1). SViCT calculates this probability
for each contig and filters out those contigs with low prob-
ability - possibly indicating a problem with assembly.
Indexing and Re-Mapping of contigs
In order to identify the mapping locations of regions origi-
nally unmappable (or incorrectly mapped) at the read level,
we re-map all the contigs to the reference genome. For this
purpose we use a sensitive, k-mer-based, seed-and-extend
approach, with a default value of k= 14. Note that the con-
tigs we consider only correspond to likely SVs and their to-
tal length is much shorter than the entire genome; an index
structure for maintaining all k-mers in the contigs is much
smaller than that of the entire reference genome. As a result
we only build a k-mer index for the contig sequences. We
then scan the reference genome to identify k-mer seeds for
potential mapping locations for each contig. A sequence of
at least some c non-overlapping but consecutive k-mer seeds
(with a gap of at most 1bp in between) are then merged into
a single ‘interval’ (of length at least 40 bp).
The above strategy will identify matching intervals be-
tween the contig and the reference with length ≥40 bp,
such that the mismatches/indels are spread with a pair-
wise distance of at least k. Contigs which have numerous
mismatches/indels in close proximity to each other are tol-
erated in interval chaining stage. Since a k-mer may be
present in a contig in multiple locations, we need to con-
sider all such locations in the contig. This process is done
for both the forward and reverse strands to account for in-
versions.
In practice, the above contig mapping approach turns out
to be much more efficient than the well known short read
mappers––due to the fact that not only the contigs are of
arbitrary length, they also typically do not have overlaps.
Many of the available read mappers do rely on the fact that
a typical read collection consists of reads of constant length,
which have overlapswithmany other reads. For example, in-
dexing and mapping of a simulated cfDNA data set respec-
tively took 53m28s and 1m21s with BWA (25); in contrast
it only took 2 s and 4 m respectively with SViCT . However,
since indexing only needs to be done once for BWA, it will
eventually be more efficient for a large number of samples.
Note that (for such cases) SViCTalso allows the user to in-
put contig mappings by any tool, including BWA, for its
next stage of SV calling. Interestingly, on the above simu-
lated data set, the use of BWA mapped contigs result in a
small drop (∼1%) in sensitivity in the SVs identified.
Interval chaining for optimal mapping
Any given contig may have several (overlapping or disjoint)
intervals that have a mapping loci in the reference. How-
ever each such interval, and thus the contig, has a single
‘true’ origin in the reference genome (provided there are no
copy number alterations associated with the interval) and
thus one ‘true’ mapping. Even though it may not be possible
to unambiguously determine the true mapping locus of any
one of the intervals in a contig, considering the ‘joint map-
ping loci’ of individual intervals may help narrowing down
the true mapping loci of the contig. SViCTuses this general
strategy by reducing the problem of contig mapping to the
optimization problem with the objective of finding the ref-
erence locus that has the maximum total interval mapping
length (and not just the number of mapping intervals, since
the interval length is not constant). Since even this strat-
egy may produce more than one solution with respect to
the above objective, SViCThas the ability to return all co-
optimal solutions.
We formulate the optimization problem above through
a weighted, directed acyclic graph (DAG), where each ver-
tex represents an interval and an edge between two vertices
indicates that the corresponding intervals are ‘compatible’.
The notion of compatibility is defined with respect to the
start and end locations of the intervals on the contig and/or
reference. Specifically, we say that two intervals A and B,
with contig locations Acstart , Acend , Bcstart , Bcend and reference
locations Arstart , Arend , Brstart , Brend , are compatible within a
user-specified uncertainty value u (=8 bp by default), if one
or more of the following hold:
‖Bcstart − Acend | − |Brstart − Arend || ≤ u,
|Bcstart − Acend | ≤ u,
|Brstart − Arend | ≤ u
The above three cases respectively correspond to inver-
sions, deletions, and duplications/insertions. We have pro-
vided an illustrative explanation for these conditions in Sup-
plementary Figure 5. Note that the edges in the DAG are al-
ways directed from upstream to downstream based on con-
tig coordinates. If one of the intervals maps to its reverse
complement, we exchange the start and end reference coor-
dinates. Finally, we add a ‘source’ and a ‘destination’ vertex
with edges to and from every other vertex in the DAG. We
set the weight of an edge to be the length of the target inter-
val and 0 weight for edges to the ‘destination’ vertex. The
solution of our optimization problem is represented by the
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Figure 2. An example execution of the algorithm for identifying chains of
compatible intervals in a multi-mapping contig. (A) The various mappings
of the contig to the reference including noise. The central blue bar indicates
the contig sequence and the surrounding bars are reference sequences. (B)
The topologically sorted, weighted (by length) DAG constructed from the
intervals above. Nodes are the intervals and edges are created if two inter-
vals are adjacent (within a given uncertainty) on either the contig or the
reference. Superfluous edges from the source and destination to all nodes
are removed for clarity. (C) The resulting paths (thick arrows) after find-
ing all co-optimal longest paths (in this case 2) from source to destination
through the DAG. The first includes an insertion and deletion on chro-
mosome A and the second includes an insertion and translocation from
chromosome B.
longest path in the DAG from the source vertex to the des-
tination vertex. This problem is solvable through a simple
greedy algorithm once the vertices are ordered via topolog-
ical sorting. Figure 2 shows how SViCTbuilds a DAG for a
given set of intervals and how it computes the (one or more)
optimal mappings.
Structural variant calling and fusion annotation
The final stage of SViCT interprets optimal contig map-
pings and predicts structural variants in two steps: (i) Iden-
tification of all classes of short SVs as well as deletions and
duplications of any length entirely contained within a single
contig. (ii) Identification of long structural variants involv-
ing two contigs.
Typically a contig has a single ‘breakpoint’ locus (derived
from split read and soft-clip mappings), except for those
contigs that include a short SV such as an inversion or an
insertion, for which there could be additional breakpoints.
If indeed the contig has a single breakpoint, step (i) iden-
tifies the closest intervals on either side of the breakpoint
and checks whether their mapping loci are in close proxim-
ity (≤5 kb by default). If they are, and there is a gap between
Deletion
Contig
Insertion Duplication
Inversion
Translocation
Figure 3. Different signatures of short SV types detectable by step (i) of
variant calling by SViCT. The centre blue bar represents the contig, and
the surrounding bars represent various genomic loci. The connecting lines
display the various ways the contig can map to these loci.
the mapping loci of the two intervals, it declares a deletion.
If there is a reversal of the order of the intervals with respect
to the mapping loci (see Figure 3), it declares a (likely tan-
dem) duplication. If one of the two sides does not have an
associated interval, this indicates a long SV, which is han-
dled in step (ii).
In case there are two (sufficiently distant) breakpoints,
step (i) first checks the possibility of a short inversion
by considering the closest intervals to either side of each
breakpoint. In case the intervals between the breakpoints
have reverse complementary matching loci on the reference
genome as per Figure 3, then step (i) calls an inversion. In
case there are no intervals between the breakpoints that
have an associated mapping locus again as per Figure 3,
then step (i) calls an insertion. In case there are intervals be-
tween the breakpoints that only have distant mapping loci
(>5 kb or in a different chromosome), then step (i) calls a
translocation. In the rare case that none of the above ap-
ply, then the two breakpoints are treated independently for
the possibility of two independent SVs covered by a single
contig.
Step (ii) involves identification of longer SVs (other than
deletions and duplications), i.e. those that are longer than
a contig length––which can only be captured by analyzing
pairs of contigs as a joint ‘signature’ of a long SV. These in-
clude longer inversions, translocations as well as insertions.
For that, step (ii) matches contig pairs for possible signa-
tures for each of these SV types. Figure 4A depicts possi-
ble contig pairs produced by translocations and inversions
- the signature for insertions are easier to locate as will be
described below.
In order to achieve this, step (ii) considers all pairs of con-
tigs that could not be handled by step (i) for further analysis
as follows. First, it considers pairs of contigs for a long in-
version signature (e.g. in Figure 4A, contig 2 could be paired
with both contig 3 and contig 5) which consists of a pair
of intervals on opposite sides of their corresponding con-
tig breakpoints, each of which mapping near the mapping
locus of the opposite contig - in a reverse complementary
manner.
Next, step (ii) considers pairs of contigs with proximal
mapping loci for a long translocation signature. Such a sig-
nature consists of a pair of intervals on opposite sides of
their corresponding contig breakpoints, which map proxi-
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Figure 4. Illustrative example of the greedy interval pair joining using eight contigs crossing two chromosomes for step (ii) of SV calling by SViCT. (A) The
darker colored intervals are ‘outer’ intervals for the lighter colored SV region, and those sharing a color are valid signatures. The lines show the mapping
of each interval to the reference chromosomes. (B) These are the corresponding intervals for the Interval Scheduling Problem. Contig 1 cannot be paired
to another contig and is not included. (C) Execution of the greedy algorithm where ‘bordered’ intervals are in the output set. Interval 1 (most upstream
end point) is selected first. Interval 2 is deleted since it overlaps with interval 1. Interval 3 and 4 are subsequently added and have no overlaps. (D) The
resulting SV calls for the compatible pairs of contigs.
mally to a distant loci (e.g. in Figure 4, contig 7 and contig
8 could be paired for a translocation signature).
Finally, step (ii) considers pairs of contigs that approxi-
mately have the same (≤u) breakpoint in terms of reference
location, one on each side of the breakpoint, each with a
corresponding unmapped suffix or prefix greater than the
anchor size (40 bp). Such a contig pair is considered to pro-
vide a long insertion signature.
Each contig can give rise to one or more SV signatures.
In order to account for the maximum number of such con-
tigs through implied SVs that do not overlap (i.e. are com-
patible), step (ii) identifies the maximum matching of con-
tig pairs––each indicating an SV signature––whose implied
SVs are all compatible (under the assumption that overlap-
ping or nested SVs do not occur; such events have been ob-
served in rare cases (26) but, as per all available SV discovery
methods, are excluded by SViCT ). See Figure 4D for exam-
ples of compatible SVs implied by pairs of contigs. This can
be formulated as a maximum interval matching problem as
per below.
Each pair of contigs can be seen as a single, long genomic-
interval (not to be confused with the notion of an ‘interval’
within a contig) spanning a chromosomal region as shown
in Figure 4B. Finding the maximum number of such non-
overlapping genomic-intervals then becomes an instance of
the (Genomic) Interval Scheduling Problem (27). The opti-
mal solution can be found using the standard greedy algo-
rithm for finding themaximum independent set of genomic-
intervals (28). (Note that it is possible to first commit to all
pairs of contigs that indicate an insertion signature since
they indicate a genomic-interval of minimum length - im-
plying that the remaining signatures are for inversions and
translocations only).
(1) Sort all genomic-intervals I by the downstream genomic
position
(2) Select the first (most upstream) genomic-interval i∈ I and
move it to the result set.
(3) Remove all genomic-intervals that overlap with i.
(4) Iterate to the next genomic-interval and continue until I
= ∅.
An example execution is shown in Figure 4C. The result is
the maximum number of compatible intervals representing
non-overlapping long SV calls (Figure 4D).
All SVs breakpoints are cross referenced against a GTF
annotation file to determine if they are located in aUTR, in-
tronic or exonic region. In cases where the structural variant
involves two breakpoints (deletions, inversions, interspersed
duplication), each breakpoint has a separate annotation, as
well as the region in between the breakpoints. For exam-
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ple, if an entire exon is deleted but both breakpoints fall
in the flanking introns, the call will be annotated as exonic
and intronic. For translocations, regions on either side of
the breakpoint are annotated separately. If breakpoints are
located in intronic/exonic regions from two distinct genes,
SViCTwill additionally annotate the SV as a fusion. The
SV breakpoint coordinates, contig information (including
support) and annotation are printed in standard VCF for-
mat.
RESULTS AND DISCUSSION
We evaluate the performance of SViCTon both simulated
and real data. The simulated cfDNA dataset was created
by generating reads from a reference with a wide variety
of inserted SVs. The real data includes the Horizon and
SeraCare reference datasets containing experimentally vali-
dated SVs. We used the former to compare with existing SV
callers and used the tool with best performance for compar-
ison in real data. Additionally, we analyzed eight CRPC pa-
tient samples in order to discover novel structural variants.
Tools were assessed on positive predictive value (PPV), sen-
sitivity and execution time.
Simulation of cfDNA datasets
In order to assess the performance of SViCT , we created
a simulated cfDNA dataset with inserted deletions, inser-
tions, inversions, duplications (tandem and interspersed)
and translocations (balanced, indel, and duplication). The
first step in generating this dataset was to create the donor
reference with SVs. We begin with the Venter genome and
create three references: normal, tumor allele1 and tumor al-
lele2. Normal is exactly the Venter genome, allele1 contains
all the SVs and allele2 contains a subset of the SVs in or-
der to simulate heterogeneity. Since we will be simulating a
targeted panel, SVs were only inserted into regions where at
least one breakpoint falls in an exonic region of some gene
in the gene panel. The algorithm to insert the SVs works as
follows. Every exon is randomly selected to contain a break-
point or not. The breakpoint is then randomly assigned a
SV type, short/long, both/allele2 and tandem/interspersed
(for duplications). If ‘short’ is selected, a length is randomly
generate between 10 and 1000. This may lead to a break-
point occurring in an intronic region. If ‘long’ is selected,
a second location is selected within an adjacent exon that
is less than 10kb away or, if no such exon exists, a length
of 1–10 kb is randomly selected. Any time a long insertion
or long interspersed duplication is generated, it has a ran-
dom chance of being added to a pool of breakpoints to be
used to generate translocations. These are then randomly
joined to create the three kinds of translocations mentioned
above, including both interchromosomal and intrachromo-
somal events. This resulted in 760 SVs, evenly distributed
between different types. Because of the re-classification of
long insertions and duplications, the distribution appears
to be skewed towards translocations. By our definition of
translocations, we believe this should be viewed as a type
encompassing large scale cases of the other types, and there-
fore would be expected to be more numerous than the other
individual types.
The second step was to generate reads using the newly
created references. This was done using the tool Wessim2
(29) for simulating whole exome sequencing reads, since,
to our knowledge, there is no read simulator tailored for
the targeted sequencing used for cfDNA. Wessim2 requires
three inputs: the reference, probe sequences and an er-
ror model. 6218 probes were obtained from Agilent Tech-
nologies for a custom design created using Agilent Sure-
Design (https://earray.chem.agilent.com/suredesign/). This
design is approximately equivalent to the Comprehensive
Cancer Design, including 105 of the 107 genes (UTRs, ex-
ons and introns). The error model was created using Gem-
SIM v1.6 (30) for the MiSeq v3 paired-end sequencing pro-
tocol. The parameters used for Wessim2 were -f 200 -d 100
-m 100, representing the fragment size, fragment size stan-
dard deviation and minimum fragment length, respectively.
Read length was specified with -l, with values 75, 100 and
150. The fragment length parameters allow us to simulate
DNA fragmentation. The parameters were selected to pro-
duce a distribution of fragment lengths close to that ob-
served in real cfDNA datasets. We selected four dilutions,
10%, 1%, 0.5% and 0.01%, for generating our simulated
samples. For the 10%, 1% and 0.5% dilutions, 4 million
reads of each read length were created from allele1/allele2
combined. For the 0.01% dilution, 70 million reads were re-
quired to be generated in order to achieve 2x ctDNA cov-
erage. This resulted in approximately 1500× overall maxi-
mum coverage (26 000× for 0.01%), 150× for the ctDNA
fraction at 10% dilution (approximately 15×, 7×, 2× for
the other dilutions, respectively) for the 100 bp read sam-
ples. The 150 and 75 bp read length samples have higher
and lower coverage, respectively, of∼±500× (and a propor-
tional difference in the dilutions). The reads were mapped
using BWA mem (25) with all default parameters.
Performance comparison
No SV detection tools currently exist which are tailored to
cfDNA data, and so we used popular, general purpose SV
callers for comparison.We compared SViCT toDelly2, Pin-
del, GRIDSS, Socrates and Lumpy2 in terms of PPV and
sensitivity. In this context, PPV is computed as the ratio of
the number of true positives (predicted breakpoint is within
10 bp of a real breakpoint) and the total number of true pos-
itives and false positives (all other calls). Sensitivity is com-
puted as the ratio of the number of true positives and the
total number of true positives and false negatives (number
of inserted SVs). Due to the uneven coverage of targeted se-
quencing, SV breakpoints may not have sufficient coverage
to be detectable, and so they are excluded from this calcula-
tion. The total number of calls with coverage are 670, 630,
528 and 289 for 10%, 1%, 0.5% and 0.01% dilutions respec-
tively.
We carefully examined the parameters of each tool for po-
tential optimizations for cfDNA data. Specifically, we mod-
ified any applicable parameter, re-ran the tool on the 150 bp,
10% sample, and compared the results in terms of F-score
(harmonic mean of PPV and sensitivity) with those ob-
tained when using the default parameters. Only Pindel ben-
efited from these optimizations and so all other tools were
executed with default parameters for all experiments. For
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Figure 5. Comparison of SViCT with other popular SV callers in terms of PPV and sensitivity for three simulated cfDNA dataset with 10% ctDNA using
various read lengths. Color shading corresponds to sequencing read lengths: 75 (lightest), 100 and 150 bp (darkest). Overall PPV is used for specific SV
types for tools that do not classify SVs (GRIDSS and Socrates). Overall PPV is used for Lumpy2 translocations to ensure PPV is not underestimated due
to BND entries matching other SV types.
Pindel, we selected -H 10 -m 10 -M 2 -x 5, which correspond
to minimum soft-clip length, minimum anchor length, min-
imum support and maximum SV length, respectively. The
first three parameters massively reduced the number of false
positives with no loss in true positives. The forth was ad-
justed for Pindel to be able to detect even the longest SVs
in our simulation (SVs up to 32 368 bp) and improved both
PPV and sensitivity. Note there is an option for predicting
long insertions, however we opt not to use it as it reduced
pindels’ precision since it produces 50%more false positives
for only 16 additional true positives.
Due to the difficulty of discovering structural variants
with such a low signal, the focus here is on sensitiv-
ity. Specifically, we did not filter the results of any of
the tools, except GRIDSS where many low support calls
(LOW QUAL) could be removed without affecting the sen-
sitivity. Also Pindel does not predict translocations and so
this SV type is excluded when calculating metrics for this
tool. SViCT , Lumpy and GRIDSS produce output in VCF
which may have breakend (BND) entries (see documenta-
tion at https://samtools.github.io/hts-specs/VCFv4.2.pdf).
These are ambiguous in terms of the type of SV so they are
matched to all SV types. Socrates uses its own output for-
mat which also does not classify breakpoints. This creates
a challenge for assessing PPV, particularly in Lumpy2 and
GRIDSS that heavily rely on BND entries. For GRIDSS
and Socrates, we can only compute overall PPV, and use
this value for each SV type in Figure 5. For Lumpy2, some
of the true positive calls explicitly match an SV type, while
others are BND entries. For this reason, using all BND calls
for computing translocation PPV would underestimate the
value, and so we use overall PPV for this SV type in Fig-
ure 5. For the other SV types, we only use the explicitly clas-
sified calls for computing PPV, and this may overestimate
the value. SViCTuses BND entries solely for translocations
and so does not have such complications.
We first ran all tools at the highest dilution (10%) as an
initial ‘easy’ test and to assess the effect of read length.
GRIDSS did the most poorly, particularly in terms of PPV.
This could be due to their reliance on OEAs and discor-
dant read pairs, which are less reliable in cfDNA data due
to often short and variable fragment lengths. Socrates is
the representative tool for using only soft-clipped reads. Its
superior performance over GRIDSS demonstrates the im-
portance of using soft-clipped reads to guide cfDNA SV
analysis. Lumpy2 fared best out of the compared tools,
but SViCToutperformed or matched Lumpy2 in every cat-
egory. This is accomplished with a competitive execution
time shown in Table 1 (Computed using a AMD FX-9590,
16GBRAM,Ubuntu Linux system). Runtime performance
is particularly good when compared to Lumpy2 in real data
where Lumpy2 takes approximately 50% longer. Most tools
were relatively unaffected by changes in read length, with
only Lumpy2 and Pindel showing some differences in per-
formance.
It should be noted that the parameters presented in the
methods either mainly affect runtime/memory (e.g. k-mer
length) or have a typical PPV/sensitivity trade off (e.g. min-
imum interval length). Since we demonstrate superior F-
score by a significant margin, the choice of parameters does
not have a major affect on the comparison. In order to pro-
vide evidence for this claim, we ran SViCTwith various val-
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Table 1. Runtime comparison of all the tested SV detection tools on the
10% ctDNA, 100 bp read length, simulated data and HD786 real data
Tool CPU time
Simulation Real
SViCT 3m27s 17m56s
Lumpy2 2m31s 28m45s
GRIDSS 6m14s 48m8s
Socrates 45s 22m5s
Delly 6m57s 7h52m40s
Pindel 9m04s 11h7m42s
ues for anchor length (a), uncertainty (u) and k-mer size (k),
and assessed overall PPV and sensitivity. As shown in Sup-
plementary Table 1, there was little difference between the
runs. Furthermore, our simulation has a comprehensive set
of SV types in a wide range of lengths. This leads us to be-
lieve that SViCT would have superior performance on any
simulated cfDNA dataset.
Next we ran all tools on datasets with lower ctDNA di-
lutions. As previously mentioned, this includes 1%, 0.5%
and 0.01% ctDNA. We used 100 bp reads for this analy-
sis as it is the median value, and as demonstrated in Fig-
ure 5, most tools are robust to changes in read length. The
results of this analysis are shown in Figure 6. PPV improved
slightly between 1% and 0.5% for SViCT , Lumpy2 and
Socrates. Socrates continued to improve at the 0.01% dilu-
tion. The remaining tools became less precise as the dilution
was reduced. sensitivity drops for most tools as expected,
but SViCT retains its margin over other tools across all di-
lutions. Delly2 showed an increase in sensitivity at the low-
est dilution, likely due to the higher overall read coverage.
This was also observed for lumpy2 deletions. All other tools
were unaffected by the increased number of normal reads. It
is particularly impressive that SViCT can retain reasonable
performance even at extremely low tumor read counts. This
indicates that our tool can handle even the most difficult
patient samples.
A total of 49 calls were only included in allele2 in this
dataset. SViCTwas able to detect 36 of these calls, and the
reduction in the number of detected calls fell at a simi-
lar rate to calls present in both alleles ( 26, 20, 4 for each
dilution respectively). This result shows that, in principle,
SViCThandle clone-specific structural variants. Addition-
ally, 14 calls have a breakpoint in an intronic region. These
calls did not cause much difficulty, with 10 being success-
fully identified ( 10, 8, 2 for each dilution respectively). Al-
though our simulation enforced one breakpoint to be ex-
onic, it is not a requirement for detection. SVs can be de-
tected in any region with read coverage, including UTRs
and introns. For comparison, Lumpy2 found fewer allele2-
only and intronic calls in all dilutions (31, 19, 10, 0 and 9,
7, 5, 0 respectively).
SV detection in real reference data
In order to evaluate SViCT real world performance, we ex-
ecuted it on two real reference datasets. They are designed
to assess the sensitivity of custom targeted sequencing as-
says. Tomake these datasets, a combination ofwild type and
variant-containing genomic DNA from standard reference
materials is created with known ratios. The reference ma-
terials are from Horizon Discovery (HD786 cfDNA at 5%
ctDNA and HD753 gDNA normal, obtained from https://
www.horizondiscovery.com/reference-standards), and Ser-
aCare (AF5, AF12, AF06 and AF01, corresponding to
four allele frequencies, 5%, 1.2%, 0.6% and 0.1%, ob-
tained from https://www.seracare.com/Controls-Reference-
Materials). HD786 is created in vitro bymixing ‘donor’ can-
cer cell lines with ‘recipient’ cell lines of different genotype.
The donor-derived cfDNA (dd-cfDNA) is meant to sim-
ulate ctDNA. SeraCare samples are created using a series
of DNA plasmids harboring known gene variants which
are inserted into a well-characterized human genomic back-
ground (GM24385) at desired molecular ratios.
All samples were sequenced using custom gene panels de-
signed to target all variants included in Horizon Discovery
reference standard, including four experimentally validated
structural variants: a deletion, an insertion and two fusions.
The deletion (E746 A750delELREA) is also included in
the SeraCare reference standard. Illumina NextSeq500 was
used to sequence each reference, and repeated to create a
replicate. For HD786, all known structural variants have
sufficient coverage to be detectable. For the deletion in the
SeraCare samples, there is a detectable signal for the 5% and
1.2% dilutions in both replicates, and for 0.6% in one repli-
cate (Run 1). A summary of these datasets is provided in Ta-
ble 2. These reads were mapped to GRCh38.86 using BWA
mem with all default parameters.
We ran all tools with identical parameters to the simu-
lation run except those to adjust the minimum variant size
since the shortest insertion is only 9 bp long. The results
for Horizon samples are shown in Table 3. SViCTwas able
to identify all four variants in HD786. Lumpy2, Socrates
and Delly2 were able to identify the fusions, but not the
insertion and deletion. Lumpy2 was only able to identify
the chr10:43114499 breakpoint, but could not identify the
correct fusion partner. Pindel was the only other tool able
to identify the insertion and deletion, but produced a very
large number of calls. Identical results were obtained be-
tween the two replicates. Unfortunately the small number of
SVs in this dataset makes it difficult to draw conclusions on
performance. However, the ability of SViCT to find all the
SVs with a relatively low number of total calls in the Hori-
zon sample certainly suggests it is effective in a real world
setting. What is quantifiable is the superior execution time,
which demonstrates the utility of the tool for the analysis of
large cohorts.
The results for SeraCare samples are shown in Table 4. As
noted earlier, in all dilutions where there was a detectable
signal, SViCTwas able to identify the aforementioned dele-
tion. On these samples, Pindel provided the best perfor-
mance among the alternative tools we tested, detecting the
deletion in both replicates of the 5% dilution and one repli-
cate of the 1.2% dilutions. As with the Horizon data, Pindel
produced an enormous amount of calls with an exceedingly
long runtime. Delly2 was also able to the detect the deletion,
but only in the highest dilution in one replicate. Other tools
were unable to identify the deletion. This result provides
additional evidence of SViCT ’s ability to detect SVs with
ctDNAproportions much lower than 5% in real data. How-
ever, in order to assess the accuracy of all tools we tested in
a systematic manner, a more comprehensive gold standard
dataset could be helpful.
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Figure 6. Comparison of SViCT with other popular SV callers in terms of PPV and sensitivity for three simulated cfDNA dataset with 100 bp read length
using various dilutions. Color shading corresponds to the ctDNA dilution: 0.01% (lightest), 0.5% and 1% (darkest). Overall PPV is used for specific SV
types for tools that do not classify SVs (GRIDSS and Socrates). Overall PPV is used for Lumpy2 translocations to ensure PPV is not underestimated due
to BND entries matching other SV types.
Table 2. Summary of real reference samples, including cfDNA concentration, number of genes in the targeted panel, approximate number of generated
paired-end reads and the approximate, per-base, average read coverage. Coverage is not uniform and may vary significantly between genes
Sample cfDNA # Genes # Reads Average read coverage
Horizon Run 1 20 ng/l 18 79 million ∼151 000×
Horizon Run 2 20 ng/l 18 46 million ∼85 000×
SeraCare Run1 10 ng/l 18 33–56 million ∼87 000×
SeraCare Run2 10 ng/l 18 44–48 million ∼85 000×
Table 3. SVs detected by SViCT and compared tools in the Horizon reference data set. Lumpy2 predicted an incorrect fusion partner and Pindel is not
designed to predict translocations
Variant Type Chr Gene Variant SViCT Lumpy2 GridSS Socrates Delly2 Pindel
Deletion 7 EGFR E746 A750delELREA Yes No No No No Yes
Insertion 7 EGFR V769 D770insASV Yes N/A No No No Yes
Fusion 4:6 ROS1 SLC34A2/ROS1 Yes Yes No Yes Yes N/A
Fusion 10 RET CCDC6/RET Yes Incorrect No Yes Yes N/A
Total Calls Run 1 3026 9967 1980 1904 4878 94 869
Total Calls Run 2 2105 8881 3463 1900 8972 75 582
Only SViCT was able to predict all four SVs. All tools found/missed the same SVs between the two replicates.
Table 4. Detection of the deletion (E746 A750delELREA) in EGFR by SViCT and compared tools in the SeraCare reference data set
Replicate Dilution SViCT Lumpy2 GridSS Socrates Delly2 Pindel
1–2 5% Yes No No No Yes* Yes
1–2 1.2% Yes No No No No Yes*
1 0.6% Yes No No No No No
Only SViCT was able to detect this deletion at all dilutions with a detectable signal (0.1% does not contain breakpoint spanning reads). An asterisk (*)
marks cases where the tool only found the deletion in one of two replicates.
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SV detection in prostate cancer patient samples
Our third dataset is targeted sequence data from cfDNA of
eight patients with metastatic, castration-resistant prostate
cancer (CRPC). A targeted panel was used including 75
prostate cancer related genes, covering exonic regions,
UTRs and intronic regions directly flanking exons (with
lower coverage). The total cfDNA concentration for each
sample was 1,500ng/l. These samples were sequenced us-
ing Illumina NextSeq producing 6–20 million, 2 × 75 bp
reads per sample. The reads were mapped to GRCh38.90
using BWAmem with all default parameters. Details of the
extraction, preparation, clinical information and specific se-
quencing depth of these samples are provided in Supple-
mentary File 1. Furthermore, we ran VarDict (31) with de-
fault parameters on all samples and matched the results to
known SNVs/SNPs from COSMIC (32) in order to pro-
vide some insight on ctDNA fractions and potential clones.
This information is also included in Supplementary File 1.
SViCTwas executed on each sample with default parame-
ters. The SV VAF is approximated by comparing the num-
ber of reads supporting a breakpoint to the total reads over-
lapping the breakpoint loci. If an SV has two breakpoints,
the sum of the read counts supporting the breakpoints is
divided by the sum of the totals. We report if we observe re-
currence and/or a call has a corresponding dbSNP (33) or
DGV (34) entry.
SViCTpredicted 1147 calls across all eight samples. Calls
with low support (<3 reads, 682 calls), and those mapping
to intergenic regions (147 calls), and repeat regions (314
calls) were filtered out. This yielded four high confidence
SV calls shown in Table 5. These calls have a high num-
ber of uniquely mapping, breakpoint-spanning reads. This
includes a novel tandem duplication in PIGU, two dele-
tions in PTEN and IKBKB, and an insertion in TMPRSS2.
PIGU (Phosphatidylinositol Glycan Anchor Biosynthesis
Class U) encodes a cell membrane protein that regulates cell
division and growth (35). PIGU is overexpressed in bladder
(36), breast (37) and prostate (38) cancers and has evidence
supporting its oncogenic role in these cancers. The duplica-
tion creates a copy of the first exon, without the start codon
and six following base pairs, ∼100 bp into the first intron
(Figure 7). The duplication excludes precisely three amino
acids from the exon, so no frameshift would be produced if
the aberrant transcript is translated. Further investigation
would be needed to establish how this could be contribut-
ing to the cancer phenotype.
Since the duplication breakpoints lie close to the exon
boundaries, computing the VAF from breakpoint reads is
unreliable. In order to investigate this further, we examined
the coverage of PIGU exons across all samples. Sample 7
has near-identical coverage of PIGU to sample 8 for exons
2–12 (Supplementary Figure 1) and does not have a dupli-
cation predicted in exon 1. Consequently, we used sample 7
as a control to more accurately determine the VAF of this
duplication. As can be seen in Supplementary Figure 2, the
coverage pattern is identical between the two samples, but
sample 8 has a clear gain (mean = 440 reads) between the
predicted breakpoints. This difference in coverage is signif-
icant when compared to the distribution of all differences
between the two samples (Student’s t-test, p< 2.2 × 10−16).
Using these differences in coverage, we computed an aver-
age VAF of 15.08% (±3.495).
PTEN, IKBKB and TMPRSS2 have well established
roles in prostate cancer. PTEN is a tumor suppressor that
negatively regulates androgen receptor (39). IKBKB is an
inflammation response gene that promotes tumor growth
and metastasis (40). As mentioned earlier, TMPRSS2 com-
monly forms fusions with ETS genes in prostate cancer
(15). No such fusions were detected in these samples, which
is not surprising given that the breakpoints of these fu-
sions typically occur in intronic regions, most of which have
zero coverage in this dataset. These three intronic calls are
detectable since they occur directly adjacent to exonic re-
gions. The deletion in PTEN is upstream of second exon of
the gene (Figure 8) and is slightly shorter than the known
germline variant esv2678342. The deletion in IKBKB is
downstream of exon four and exactly matches the germline
variant rs143122536. The insertion in TMPRSS2, occurring
directly downstreamof exon eleven (Figure 9), was observed
in all samples. Since this region of TMPRSS2 is generally
unimportant for its oncogenic role, this variant likely has
no effect on the phenotype.
We also ran Lumpy2 on the same eight samples with de-
fault parameters. Lumpy2 was able to identify the dupli-
cation and deletions, but not the insertion. Furthermore
Lumpy2made over 47 000 predictions across the eight sam-
ples, while SViCTpredicted 1147, indicating a much higher
false positive rate. Indeed on closer inspection, many of
Lumpy2’s high confidence calls are false positives caused
by misinterpretation of long fragments or over-estimation
of support due to PCR duplicates. The former is appar-
ent from a very large number of deletion predictions with
no breakpoint spanning reads. The latter case can be seen
on investigation of the supporting reads, which all have
identical sequence in many instances. PCR duplicates can
be remove using tools such as Picard (http://broadinstitute.
github.io/picard), but even with such filtering Lumpy2 pre-
dicted over 9000 SVs while SViCTpredicted 375 without
loss of the high confidence calls. There were no high con-
fidence calls in the 9000 SVs that were not also identified by
SViCT . This result demonstrates that even excellent tools
such as Lumpy2 can be confounded by the unusual prop-
erties of cfDNA. In this pilot study, SViCTwas able to dis-
cover known structural variants and a potentially novel du-
plication. Analysis of larger cohorts will reveal the true util-
ity of SViCT , but these results certainly suggest the tool can
successfully detect structural variants using cfDNA.
Identification of genomic alterations is becoming increas-
ingly important in the treatment paradigm of patients with
metastatic prostate cancer. As oncologists perform earlier
genomic testing during the disease course, identifying mu-
tations and structural variations that can potentially make
tumors susceptible to certain targeted and biologic ther-
apies is of paramount importance. Moreover, identifying
the evolution of mutations over time through serial liq-
uid biopsies will give further insight regarding the opti-
mal treatment of each patient with metastatic prostate can-
cer in the era of precision medicine. We believe that exist-
ing approaches designed for typical sequencing data from
solid tumor biopsies are insufficient to accurately identify
SVs in this context. SViCT improves on these approaches,
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Exon 1 UTRIntron
Exon 1 UTRIntronExon 1 DupIntron
          CAGACTGGAGCGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACAGTCTGCTCGAG
          CAGACTGGAGCGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCC
                GACTGGAGCGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCA
                     CTGGAGCGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATT
                          GGAGCGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCA 
                                AGCGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACA
                                      CGGAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGA
                                           GAACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGG
                                                ACAAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCC
                                                     AAGGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGC
                                                          GGCCGCCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGG               
                                                                        CCCGCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGG
                                                                               GCACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAG
                                                                                  CACTGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGG
                                                                                          TGTCACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGG
                                                                                                 CACAGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGC
                                                                                                        AGCCACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTG
                                                                                                                CACCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACA
                                                                                                                     CCACCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACAGT
                                                                                                                             CCAGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACAGTCTG
                                                                                                                                  AGCACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACAGTCTGCT
                                                                                                                                       CACCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACAGTCTGCTCG
                                                                                                                                            CCAGGACCAAGGG CCCCCGCCTCCCATTCACAGAGGCCGCGGGAGGGCAGGTGGGGCCTGACAGTCTGCTCGAG
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Figure 7. Illustration of the novel tandem duplication discovered in sample eight of the CRPC cohort rearranging the cancer oncogene PIGU. The du-
plicated region is colored in green, which contains a part of the first intron and the entire first exon, except the start codon (red) and a few base pairs. A
sample of the reads supporting the event is shown at the bottom of the figure.
Table 5. High confidence SV predictions for the eight prostate cancer patient samples
Type Sample Gene Region Chr Start End
Read
support VAF DGV dbSNP
Duplication 8 PIGU Exon 20 34676880 34677076 48 11.58–18.57% – –
Deletion 5 PTEN Intron 10 87893068 87893965 47 64.50% esv2678342* –
Deletion 6, 8 IKBKB Intron 8 42290344 42290377 124, 86 37.2%, 33.7% – rs143122536
Insertion All TMPRSS2 Intron 21 41470789 41470789 32–60 50.7–60.5% – rs112132031
The read support is the number of unique reads only; PCR duplicates are removed. (*) The DGV variant is slightly longer than the one discovered here.
with superior performance on a wide range of ctDNA di-
lutions and read lengths, both in simulated and real data.
This suggests that SViCT can robustly handle the variabil-
ity expected in clinical setting and be an effective tool for
personalized medicine.
The largest limitation of this approach for clinical ap-
plication is the sequencing itself. For cases with very low
ctDNA signal the allele frequency may be close to the er-
ror rate. Furthermore, the reliance on PCR may result in
false signals from early PCR errors and biases. One way
to resolve these issues is through the use of unique molec-
ular identifiers (UMIs) which are random sequences (bar-
codes) of fixed length appended to DNA molecules prior
to amplification (41). The aim is to be able to cluster reads
which were derived from the same molecule through these
barcodes. After clustering, PCR duplicates and sequencing
errors can be effectively removed, typically by determin-
ing a consensus read for each cluster. Tools such as UMI-
Tools (42) and Calib (43) can accomplish this task. This in-
creases confidence in predictions made with very low allele
frequency. Using such barcoding techniques would improve
the utility of SViCTunder these circumstances.
CONCLUSION
Here we demonstrated that SViCT can efficiently and effec-
tively handle sequencing data from cfDNA samples. It is re-
silient to high read depth since all reads are essentially ‘col-
lapsed’ into contigs. Reasonable sensitivity is maintained
even at very low dilutions of ctDNA with the ability to
detect SV signatures with as little as two reads. The good
sensitivity can, in principle, allow for detection of allele-
specific or clone-specific SV signatures, provided paired
normal data is available for accurate VAF estimation. This
is achieved while producing fewer false positives than any
other tool, removing the need for additional filtration. Fi-
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Exon 2
                         CCCTTGAACAACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAAGTACTCAGATATT
                         CCCTTGAACAACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTT
                              CTTGAACAACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGA
                TGAACAACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATT
                     AACAACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGC
                          CAACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTG
                               ACACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCA
                                            ACAGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATA
                                                   AGAGGGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATT
                                                                  GGTAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAG
                                                                          TAGGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGAT
                                                                                 GGGGCGCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATAT
                                                                                 GCCTACCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTT
                                                                                                    CCCCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTT
                                                                                                           CCTGTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAA
                                                                                                                     GTGCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTA
                                                                                                            GCAGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAA
                                                                                                                   AGTTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAAGT
                                                                                                                       TTGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAAGTAC
                                                                                                                          TGAAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAAGTACT
                                                                                                                                 AAAATTCACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAAGTACTCA
                                                                                                                                                            CACATGTAACTT CTTTTAGTTTGATTGCTGCATATTTCAGATATTTCTTTCCTTAACTAAAGTACTCAGATATT
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4
Intron 1
Chr10   87893068                                                                      87893965
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Figure 8. Illustration of the deletion discovered in sample five of the CRPC cohort in the tumor suppressor PTEN. The deleted region is colored in green,
which falls in intron one upstream of the second exon. A sample of the reads supporting the event is shown at the bottom of the figure.
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                     CTGTTTCAAGAAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGCCACCCTGCCC
                     CTGTTTCAAGAAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCC
                          GTTTCAAGAAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTT
                               TTCAAGAAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCC
                                    CAAGAAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCA
                                         AGAAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACA
                                              AAGAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATG
                                                   GAGAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCA
                                                        GAAAACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGG
                                                                AACACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTG
                                                                     CACAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCT
                                                                          CAGTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGG
                                                                               GTGAGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGC
                                                                                       AGCCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTG
                                                                                             CCAGGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGC
                                                                                                     GGCGGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACC
                                                                                                             GGGTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTG
                                                                                                                   GTATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGC
                                                                                                                        ATCACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGCCA
                                                                                                                            CACCTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGCCACC
                                                                                                                                    CTAAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGCCACCCTG
                                                                                                                                         AAGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGCCACCCTGCC
                                                                                                                                            AGGCCTCGGGCTATGTCTCCACCTGGCCTTCCCACATGCAGGCTGCTGGGCCTGGCACCCTGGCCACCCTGCCC
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8
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Figure 9. Illustration of the insertion discovered in all samples of the CRPC cohort in the gene TMPRSS2. The inserted region is colored in green, which
falls in intron ten downstream of exon eleven. A sample of the reads supporting the event is shown at the bottom of the figure.
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nally, the ability of the algorithm to find a small set of op-
timal interval sets for each contig makes it robust in terms
of noise. For these reasons, SViCT is another step toward
a comprehensive suite of tools for analyzing cfDNA. This,
and other efforts in cfDNA analysis, will help progress pre-
cision medicine and reduce reliance on dangerous and inva-
sive biopsies.
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